Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry

Filippo, Ovidio De; Cortese, Martina; ́ascenzo, Fabrizio D; Raposeiras‐Roubín, Sergio; Abu‐Assi, Emad; Kinnaird, Tim; Arizá-Solé, Albert; Manzano‐Fernández, Sergio; Templin, Christian; Velicki, Lazar; Xanthopoulou, Ioanna; Cerrato, Enrico; Rognoni, Andrea; Boccuzzi, Giacomo; Montefusco, Antonio; Montabone, Andrea; Taha, Salma; Durante, Alessandro; Gili, Sebastiano; Autelli, Michele; Grosso, Alberto; Blanco, Pedro J.; Garay, Alberto; Quadri, Giorgio; Varbella, Ferdinando; Queija, Berenice Caneiro; Paz, Rafael Cobas; Fernández, María Cespón; Pousa, Isabel Muñoz; Gallo, Diego; Morbiducci, Umberto; Valdés, Mariano; Cequier, Ángel; Alexopoulos, Dimitrios; Íñiguez‐Romo, Andrés; Rinaldi, Mauro

doi:10.1007/s40256-019-00339-3

Cited by 18 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar incidences of recurrent MI and major bleedings were found for both prasugrel and ticagrelor treated patients. [16] Our study showed no difference in comparative effectiveness or safety at 1 year between prasugrel and ticagrelor treatment. Prior observational studies have shown deviating results in comparison of prasugrel and ticagrelor.…”

Section: Prasugrel Vs Ticagrelorcontrasting

confidence: 50%

“…ticagrelor at 1 year among real-life ACS patients (68% STEMI), all-cause mortality among prasugrel treated patients was slightly lower in our study. [16] This could be due to the study design (inclusion of patients alive >7 days after discharge) and since prasugrel treated patients had fewer comorbidities and more often received drug eluting stents (81% compared with 56%). [16] Mortality rates were comparable for ticagrelor treated patients, possibly due to higher age in our cohort.…”

Section: Prasugrel Vs Ticagrelormentioning

confidence: 99%

“…[16] This could be due to the study design (inclusion of patients alive >7 days after discharge) and since prasugrel treated patients had fewer comorbidities and more often received drug eluting stents (81% compared with 56%). [16] Mortality rates were comparable for ticagrelor treated patients, possibly due to higher age in our cohort. Similar incidences of recurrent MI and major bleedings were found for both prasugrel and ticagrelor treated patients.…”

Section: Prasugrel Vs Ticagrelormentioning

confidence: 99%

“…Prior observational studies have shown deviating results in comparison of prasugrel and ticagrelor. [16,17] One RCT comparing ticagrelor and prasugrel among mostly patients with STEMI treated with PPCI evaluated early efficacy and safety (7 days post discharge) but was stopped prematurely. [18] Superiority of prasugrel over ticagrelor has been demonstrated.…”

Section: Prasugrel Vs Ticagrelormentioning

confidence: 99%

See 3 more Smart Citations

Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

Jacobsen¹,

Engstrøm²,

Torp‐Pedersen³

et al. 2021

International Journal of Cardiology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Prasugrel Vs Ticagrelorcontrasting

confidence: 50%

Section: Prasugrel Vs Ticagrelormentioning

confidence: 99%

Section: Prasugrel Vs Ticagrelormentioning

confidence: 99%

Section: Prasugrel Vs Ticagrelormentioning

confidence: 99%

See 2 more Smart Citations

Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

Jacobsen¹,

Engstrøm²,

Torp‐Pedersen³

et al. 2021

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…Another real-word European study (RENAMI Registry) reported the clinical benefit of prasugrel use in patients with ACS after percutaneous coronary intervention (PCI) and discussed the superiority of prasugrel over ticagrelor in patients with NSTEMI after propensity score matching [18]. Further, a previous prospective, observational, multicenter cohort study presented lower cardiovascular adverse events for NSTEMI patients taking prasugrel compared to those with ticagrelor after undergoing a PCI [10].…”

Section: Discussionmentioning

confidence: 99%

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017

Rezaei

Gleiß

Reichardt³

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Dual antiplatelet therapy improves patient outcome after acute coronary syndrome (ACS), but prescription differences of P2Y12 inhibitor treatments exist. The aim of the present investigation was to study the long-term utilization and patient outcomes of clopidogrel, prasugrel, and ticagrelor in patients with ACS from 2015 to 2017 in Austria. Methods: Data from 13 Austrian health insurance funds of patients with a hospital discharge diagnosis of ACS for the years 2015 to 2017 were analyzed. The primary end point was to investigate the recurrence of ACS or death. Results: Of 49,124 P2Y12 inhibitor-naive patients with a hospital discharge diagnosis of ACS, 25,147 subjects filled a P2Y12 inhibitor prescription within 30 days after the index event. Of these patients, 10,626 (42.9%) subjects had a prescription for clopidogrel, 4788 (19.3%) for prasugrel, and 9383 (37.8%) for ticagrelor. Ticagrelor was the most frequently prescribed P2Y12 inhibitor among patients below 70 years old, and clopidogrel in those aged ≥70 years. Occurrence of an endpoint was highest in elderly patients. After adjustment for age, sex, and pre-existing medication as proxy for comorbidity, the hazard ratio for ACS or death for prasugrel vs. clopidogrel of 0.70 (95% CI: 0.61; 0.79) was similar to that of ticagrelor vs. clopidogrel (0.70; 95% CI: 0.64; 0.77). Conclusion: Prescription of ticagrelor or prasugrel after ACS were associated with a lower risk of ACS recurrence or death compared to clopidogrel.

show abstract

Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome

Wu,

Huang

et al. 2024

J Thromb Thrombolysis

View full text Add to dashboard Cite

Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry

Cited by 18 publications

References 30 publications

Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017

Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome

Contact Info

Product

Resources

About